The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...
Disruptions in transcriptional regulation during hematopoiesis can lead to abnormal hematopoietic differentiation and the development of leukemia. Understanding the underlying mechanisms of disease ...
– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occur in approximately 30% of ...
Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have ...
Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic mutations—IDH2 and SRSF2—work cooperatively to mis-splice RNA messages and ...
Researchers have led a global study that identified molecular predictors of survival among Black patients with acute myeloid leukemia (AML). The study suggests a need to modify current AML risk layers ...
Black race is an independent prognostic factor for lower survival outcomes in AML, regardless of cytogenetics. Black patients with NPM1 mutations had poorer overall survival compared to White patients ...
Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results